Neuropsychological rehabilitation for multiple sclerosis
Abstract Background This is an update of the Cochrane review ‘Neuropsychological rehabilitation for multiple sclerosis’ (first published in The Cochrane Library2011, Issue 11). Cognitive deficits are a common manifestation of multiple sclerosis (MS) and have a significant effect on the patient’s quality of life. Alleviation of the harmful effects caused by these deficits should be […]
Mycophenolate mofetil for relapsing-remitting multiple sclerosis
Abstract Background Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system and a leading cause of disability in young and middle-aged adults. Mycophenolate mofetil (MMF) is an immunosuppressive agent that has been used for the prevention of allograft rejection after renal, cardiac, or liver transplant and in patients with autoimmune diseases such […]
Management of faecal incontinence and constipation in adults with central neurological diseases
Abstract Background People with central neurological disease or injury have a much higher risk of both faecal incontinence and constipation than the general population. There is often a fine line between the two symptoms, with any management intended to ameliorate one risking precipitating the other. Bowel problems are observed to be the cause of much […]
Daclizumab for relapsing remitting multiple sclerosis
Abstract Background Monoclonal antibodies such as daclizumab could be a possible alternative immunotherapy to interferon beta treatment in people with multiple sclerosis (MS). It blocks the interleukin-2 receptor alpha subunit (CD25), and seems to be beneficial to patients with relapsing remitting multiple sclerosis (RRMS) in clinical and magnetic resonance imaging (MRI) measures of outcomes. This […]
Pharmacological treatment for memory disorder in multiple sclerosis
Abstract Background This is an update of the Cochrane review “Pharmacologic treatment for memory disorder in multiple sclerosis” (first published in The Cochrane Library 2011, Issue 10). Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, demyelinating, neurodegenerative disorder of the central nervous system (CNS) and can cause both neurological and neuropsychological disability. Both demyelination and […]
Rituximab for relapsing-remitting multiple sclerosis
Abstract Background This is an update of the Cochrane review “Rituximab for relapsing-remitting multiple sclerosis” (first published in The Cochrane Library 2011, Issue 12). More than 80% of individuals with multiple sclerosis (MS) experience a relapsing-remitting disease course. Approximately 10 years after disease onset, an estimated 50% of individuals with relapsing-remitting MS (RRMS) convert to […]
Laquinimod for multiple sclerosis
Abstract Background Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, demyelinating, neurodegenerative disorder of the central nervous system, and it causes major socioeconomic burden for the individual patient and for society. An inflammatory pathology occurs during the early relapsing stage of MS and a neurodegenerative pathology dominates the later progressive stage of the disease. Not […]
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Abstract Background Different therapeutic strategies are available for treatment of multiple sclerosis (MS) including immunosuppressants, immunomodulators, and monoclonal antibodies. Their relative effectiveness in the prevention of relapse or disability progression is unclear due to the limited number of direct comparison trials. A summary of the results, including both direct and indirect comparisons of treatment effects, […]
Mitoxantrone for multiple sclerosis
Abstract Background Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity in multiple sclerosis (MS) patients. This is an update of the Cochrane review “Mitoxantrone for multiple sclerosis” (published on Cochrane Database of Systematic Reviews 2013, Issue 5). Objectives The main objective was to assess the […]
Non pharmacological interventions for spasticity in multiple sclerosis
Abstract Background Spasticity is commonly experienced by people with multiple sclerosis (MS), and it contributes to overall disability in this population. A wide range of non pharmacological interventions are used in isolation or with pharmacological agents to treat spasticity in MS. Evidence for their effectiveness is yet to be determined. Objectives To assess the effectiveness […]